Current evidence supports that SGLT2-is can reduce the risk of MI, while the risks of unstable angina, stroke, TIA, arterial revascularization, and PAD seem to be unaffected by SGLT2-is. The gene discussed is SLC5A2; the disease is stroke disorder.